<DOC>
	<DOCNO>NCT02961751</DOCNO>
	<brief_summary>Data clinical study use assess treatment approach meet CDC criterion become recommend treatment ( cure rate great 95 percent low CI:95percent great 95 percent ) alternative treatment ( cure rate great 95 percent low CI95 percent great 90 percent ) uncomplicated gonococcal infection . An estimated cure rate 0.98 . A single-arm clinical study design , allow 10 percent subject drop-out rate 10 percent non-evaluable rate . Screening Visit include NG NAAT ; Baseline Visit Day 1 include NG NAAT culture ; Test Cure Visit Day 6 include NG NAAT culture . The primary objective study determine efficacy ciprofloxacin treatment uncomplicated N. gonorrhoeae infection gyrA serine 91 genotype .</brief_summary>
	<brief_title>Clinical Validation Molecular Test Ciprofloxacin-Susceptibility Neisseria Gonorrheaoe</brief_title>
	<detailed_description>This study multi-center , single-arm , open-label clinical study ass efficacy one dose ciprofloxacin give orally subject infect untreated gyrA serine 91 genotype N. gonorrhoeae determine real-time PCR assay . The study enroll approximately 381 subject obtain per protocol eligible target 257 subject age 18 old regardless gender identification seek care STD clinic participate site United States . Subjects untreated gyrA serine 91 genotype N. gonorrhoeae rectum , male female urogenital tract identify positive culture NAAT conduct prior visit offer enrollment study . Subjects consent participate study receive treatment per local standard care . The primary objective study determine efficacy ciprofloxacin treatment uncomplicated N. gonorrhoeae infection gyrA serine 91 genotype . The secondary objective study 1 ) investigate efficacy ciprofloxacin treatment uncomplicated serine 91 gyrA N. gonorrhoeae infection anatomic site 2 ) determine sensitivity gyrA assay detection ciprofloxacin-susceptible N. gonorrhoeae infection .</detailed_description>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Willing able give voluntary write informed consent study related procedure perform . 18 year old , inclusive , day enrollment . Untreated gyrA serine 91 genotype N. gonorrhoeae rectum , male female urogenital tract , determine gyrA test assay specimen collect within 30 day enrollment . Subjects must gyrA serine 91 genotype detect N. gonorrhoeae least one nonpharyngeal site . Willing abstain sexual intercourse use condom sexual contact Test Cure Visit ( Visit 2 , Day 59 ) complete . Women childbearing potential must practice highly effective method contraception 30day period enrollment agree continue followup complete . A woman childbearing potential unless postmenopausal ( great 2 year ) surgically sterilize ( tubal ligation great 1 year , bilateral oophorectomy , hysterectomy ) . Acceptable birth control method purpose study may include abstinence intercourse male partner , monogamous relationship vasectomize partner , male condom use applied spermicide , intrauterine device , license hormonal method . A highly effective method contraception define one result low failure rate ( i.e. , less 1 percent per year ) use consistently correctly . Able swallow pill . Willing comply protocol requirement , include availability followup duration study . Agree avoid systemic intravaginal antibiotics* activity N. gonorrhoeae enrollment Visit 2 ( Day 59 ) . *Topical intravaginal antifungal permit . Agree avoid magnesium/aluminum antacid , sucralfate , didanosine , highly buffer drug , product contain calcium , iron , zinc 2 hour receipt study drug . Known renal insufficiency clinical history . Use systemic intravaginal antibiotic potential activity N. gonorrhoeae within 30 day prior study drug administration Topical intravaginal antifungal permit . Use systemic corticosteroid drug immunosuppressive therapy within 30 day prior enrollment . Receipt plan receipt investigational product clinical trial within 30 day prior 7 day treatment administration . Pregnant breastfeeding . Clinical diagnosis pelvic inflammatory disease genital ulcer . Confirmed suspect complicate systemic gonococcal infection , abdominal pain , testicular pain , epididymitis , orchitis , arthritis , endocarditis.Receipt magnesium/aluminum antacid , sucralfate , didanosine , highly buffer drug , product contain calcium , iron , zincwithin 6 hour receipt study drug . Mutant N. gonorrhoeae gyrA serine 91 genotype anatomic site , determine gyrA test assay specimen collect within 30 day enrollment . Known allergy history adverse reaction ciprofloxacin . Known allergy quinolones . Previous enrollment study . Medical condition factor judgment investigator might affect ability comply procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 27, 2016</verification_date>
	<keyword>Ciprofloxacin-susceptibility</keyword>
	<keyword>Gyrase A Assay</keyword>
	<keyword>Neisseria gonorrhoeae</keyword>
</DOC>